Skip to main content
. 2021 Nov 17;10(22):5359. doi: 10.3390/jcm10225359

Table 3.

Comparison of IBD patients’ parameters with coexisting identified liver pathology or idiopathic liver pathology.

Parameter Patients with Identified Liver Pathology (n = 14) Patients with Idiopathic Liver Pathology (n = 7)
Age, median (range), years 11.5 (3–16) 16 (10–17)
Sex, no. of female (%) 6 (43%) 3 (43%)
IBD type, n (%)

  • CD

 4 (29%) 3 (43%)

  • UC

 10 (71%) 4 (57%)
IBD activity at the time of liver pathology diagnosis, median (range), score

  • PCDAI

 5 (2.5–10) 5 (5–15)

  • PUCAI

 25 (0–60) 57.5 (55–70)
IBD activity at the time of liver pathology diagnosis, n (%)

  • Remission

 7 (50%) 2 (29%)

  • Mild

 4 (29%) 1 (14%)

  • Moderate

 3 (21%) 3 (43%)

  • Severe

 0 1 (14%)
Time of liver pathology diagnosis in relation to IBD diagnosis, n (%)

  • Preceding

 3 (21%) 0

  • Concomitant

 3 (21%) 4 (57%)

  • After

 8 (57%) 3 (43%)
  • ○

    1–3 months

 0 3
  • ○

    4–6 months

 0 0
  • ○

    more than 6 months

 8 0
ALT (U/L), median (range) 73 (32–805) 44 (20–86)
GGT (IU/L), median (range) 44 (14–418) 49 (13–135)
WBC (103/µL), median (range) 10.66 (6.11–28.7) 9.75 (4.87–20)
PLT (103/µL), median (range) 422.5 (308–547) 312 (210–676)
Liver abnormalities in imaging studies, n (%) 11 (79%) 1 (14%)

NS—nonsignificant, IBD—inflammatory bowel disease, CD—Crohn’s disease, UC—ulcerative colitis, PCDAI—pediatric Crohn’s disease activity index, PUCAI—pediatric ulcerative colitis activity index, ALT—alanine transaminase, GGT—gamma-glutamyl transpeptidase, WBC—white blood cells, PLT—platelets.